Glenmark Pharmaceuticals ltd — Capital/Financing Update 2021

Aug 6, 2021

==> picture [140 x 42] intentionally omitted <==

August 6, 2021

To, Dy. General Manager Department of Corporate Services, BSE Ltd. Phiroze Jeejeeboy Towers Dalal Street, Fort Mumbai – 400001 Ref: Scrip Code No: 532296

To, The Manager‐Listing National Stock Exchange of India Ltd., Plot No. C/1, G Block, Bandra Kurla Complex (BKC) Bandra (east) Mumbai – 400051 Ref: Scrip Name: GLENMARK

Dear Sirs/Madam,

Sub: Update on listing of equity shares of Glenmark Life Sciences Limited

This is further to our intimations dated April 16, 2021, July 20, 2021 and August 3, 2021, on the subject mentioned above, we would like to inform you that the equity shares of the wholly owned subsidiary of the Company, Glenmark Life Sciences Limited, were admitted for listing by BSE Limited and National Stock Exchange of India Limited with effect from August 6, 2021.

We request you to kindly take the above information on record.

Thanking you,

Yours faithfully,

For Glenmark Pharmaceuticals Limited

==> picture [65 x 47] intentionally omitted <==

Harish Kuber

Company Secretary and Compliance Officer

Tel: 4018 9999 / 4018 9879 Fax: 4018 9986 (Legal & Secretarial Dept.)

Glenmark Pharmaceuticals Ltd. Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com